This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Drug Therapy  • Adverse Effects  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Maria del Pilar Martin, PhD; Petra D. Cravens, PhD; Ryan Winger; Elliot M. Frohman, MD, PhD; Michael K. Racke, MD; Todd N. Eagar, PhD; Scott S. Zamvil, MD, PhD; Martin S. Weber, MD; Bernhard Hemmer, MD; Nitin J. Karandikar, MD, PhD; B. K. Kleinschmidt-DeMasters, MD; Olaf Stüve, MD, PhD

Arch Neurol. 2008;65(12):1596-1603. Published online October 13, 2008 (doi:10.1001/archneur.65.12.noc80051).

Objective  To extend our studies on the prolonged and differential effect of natalizumab on T lymphocyte numbers in the cerebrospinal fluid, we investigated the number and phenotypes of leukocytes and the expression of major histocompatibility complex (MHC) classes I and II in cerebral perivascular spaces (CPVS). We hypothesized that natalizumab reduces the number of antigen presenting cells in CPVS.

Design  A case-control study in which inflammatory cell numbers in the CPVS of cerebral tissue were assessed by immunohistochemical staining.

Subjects  A patient with multiple sclerosis (MS) who developed progressive multifocal leukoencephalopathy (PML) during natalizumab therapy. Controls included location-matched cerebral autopsy material of patients without disease of the central nervous system, patients with MS not treated with natalizumab, and patients with PML not associated with natalizumab therapy.

Results  The absolute number of CPVS in the patient with MS treated with natalizumab was significantly lower than in the control groups owing to extensive destruction of the tissue architecture. The expression of MHC class II molecules and the number of CD209⁺ dendritic cells were significantly decreased in the CPVS of the patient with MS treated with natalizumab. No CD4⁺ T cells were detectable.

Conclusions  Our observations may explain the differential and prolonged effects of natalizumab therapy on leukocyte numbers in the cerebrospinal fluid.

Author Affiliations: Departments of Neurology (Drs Martin, Cravens, Frohman, Eagar, and Stüve and Mr Winger), Ophthalmology (Dr Frohman), Immunology (Drs Eagar, Karandikar, and Stüve), and Pathology (Dr Karandikar), University of Texas Southwestern Medical Center at Dallas; Departments of Neurology, The Ohio State University Medical Center, Columbus (Dr Racke), University of California, San Francisco (Drs Zamvil and Weber), and Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany (Drs Weber and Hemmer); Departments of Pathology, Neurology, and Neurosurgery, University of Colorado, Denver (Dr Kleinschmidt-DeMasters); and the Neurology Section, Veterans Affairs North Texas Health Care System, Medical Service, Dallas (Dr Stüve).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLES

This Month in Archives of Neurology
Arch Neurol. 2008;65(12):1564-1565.
FULL TEXT  

Central Nervous System Immune Surveillance: On Natalizumab, Dendritic Cells, and Dangerous Immune Privilege
Burkhard Becher
Arch Neurol. 2008;65(12):1566-1567.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes
Wiendl and Hohlfeld
Neurology 2009;72:1008-1015.
ABSTRACT | FULL TEXT  

Review: Natalizumab in the treatment of multiple sclerosis
Yaldizli and Putzki
Therapeutic Advances in Neurological Disorders 2009;2:115-128.
ABSTRACT  

Central Nervous System Immune Surveillance: On Natalizumab, Dendritic Cells, and Dangerous Immune Privilege
Becher
Arch Neurol 2008;65:1566-1567.
FULL TEXT